Hims & Hers Health (HIMS) fundamentals: P/E, valuation, undervalued?
Hims & Hers Health · Health Care · ref. ETF XLV · price $31.66
In short — Hims & Hers Health trades at —× earnings (P/E), 28.4× forward, with a net margin of -5.5 % and revenue growth of +38 %. Read: Not (yet) profitable (valued on growth, not earnings).
Is Hims & Hers Health stock cheap or undervalued? A good time to buy? Here are its fundamentals — P/E, PEG, margin and income statement — to judge its valuation.
📈 1-year price
$31.66-28.2% over range
Aug 28, 25low $14.52 · high $62.76Aug 27, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Hold
33% recommend buying · 12 analysts
Valuation : Not (yet) profitable — valued on growth, not earnings
Valuation
—
P/E (price/earnings)
28.4
Forward P/E
—
PEG
22.8
Price/book (P/B)
$7.4B
Market cap
-0.68
EPS
Profitability & growth
-5.5 %
Net margin
+38 %
Revenue growth
—
Earnings growth
$1.5B
Total debt
Hims & Hers Health income statement
| Fiscal year | Revenue | Net income | Margin |
|---|---|---|---|
| 2022 | $527M | $-66M | -12.5 % |
| 2023 | $872M | $-24M | -2.7 % |
| 2024 | $1.5B | $126M | 8.5 % |
| 2025 | $2.3B | $128M | 5.5 % |
⚠️ Indicative financial data (Yahoo Finance), not investment advice. Amounts in $.
Frequently asked questions
What is Hims & Hers Health's P/E and is the stock undervalued? What's a good P/E?
Hims & Hers Health's P/E is — (forward 28.4). Below ~15 = fairly cheap, above ~30 = expensive. Our valuation verdict: "Not (yet) profitable".
Is Hims & Hers Health profitable?
Hims & Hers Health has a net margin of -5.5 % (EPS -0.68). The company is not (yet) profitable.
Is HIMS stock expensive?
Our read: "Not (yet) profitable" — valued on growth, not earnings. Cross-check with growth and sector.
💬 A question about Hims & Hers Health? The JPI assistant answers using our backtest data.